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Accurate, selective and sensitive stability indicating high performance thin layer chro-
matographic (HPTLC) method was developed and validated for determination of Metopi-
mazine (MPZ) in presence of its degradation products; including the oxidative degradation
product (Deg I) and the alkaline hydrolysis degradation product (Deg II; formerly reported
as acid metabolite). The proposed method was applied for analysis of MPZ in pure form,
pharmaceutical formulation (tablets) and human plasma over the concentration range of
0.4e1.4 mg band1 with accuracy of mean percentage recovery 100.10  0.941. The method
depends on separation of MPZ from its degradation products on HPTLC silica gel 60 F254
plates using chloroformemethanoleammonia (12:2:0.1, by volume) as developing system
followed by densitometric measurement of bands at 254 nm. The method was validated
according to ICH guidelines. The degradation products were well resolved from the pure
drug with significantly different Rf values (MPZ, Rf ¼ 0.58, Deg I, Rf ¼ 0.35 and Deg II,
Rf ¼ 0.03). The results obtained by the proposed method were statistically compared to the
reported HPTLC method, and there was no significant difference between them regarding
both accuracy and precision; indicating the ability of the proposed method to be used for
routine analysis of drug product.
Copyright 2014, Beni-Suef University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Metopimazine (MPZ); chemically is, 1-[3-[2-(methylsulfonyl)-
10 H-phenothiazin-10-yl]propyl]-4-piperidinecarboxamide.
m.bsu.edu.eg, ibrahimna
i-Suef University
sevier
ity. Production and host(Budavaried, 2006). It is a phenothiazine dopamine antago-
nist that acts as antiemetic with general properties similar to
those of chlorpromazine. It is used in the management of
nausea and vomiting, including that associated with cancer
chemotherapy (Martindale, 2005); Fig. 1.guib1979@yahoo.com (I.A. Naguib).
ing by Elsevier B.V. All rights reserved.
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ported for quantitative estimation of MPZ including pharma-
copoeial non aqueous titrimetric method (Pharmacopee
Francaise, 1985), HPLC method for analysis of MPZ in human
plasma in presence of its acidmetabolite (Deg II) (Angelo et al.,
1989), TLC densitometric method for determination of MPZ in
pure and dosage form in presence of its oxidative degradation
product (Deg I) (Metwally et al., 2006) and differential pulse
voltammetric method for determination of MPZ and floctafe-
nine (Gazy et al., 2007).
Current ICH guidelines requires that stability study should
be done using developed and validated stability indicating
assay methods after stress testing on drugs under a variety of
conditions (ICH, 2005). Accordingly MPZ was subjected to
oxidation and hydrolysis, and the obtained degradation
products were separated and identified; Figs. 1e3. No method
was reported for determination of MPZ in presence of both
oxidative and alkaline degradation products, where, the re-
ported HPLC (Angelo et al., 1989) and TLC (Metwally et al.,
2006) methods measured MPZ in presence of only one of the
degradation products. Moreover; the reported TLC (Metwally
et al., 2006) and voltammetric (Gazy et al., 2007) methods
were not applied for determination of MPZ in plasma. There-
fore, it was essential to develop a simpler and more selective
method for determination of MPZ in presence of its different
degradation products.
The aim of this work is to develop simple and accurate
stability indicating HPTLC method that is cheaper and moreFig. 1 e Degradation pattern of Metopimazine to its oxidaselective than any reported method for determination of MPZ
in presence of its oxidative (Deg I) and alkaline (Deg II)
degradation products without preliminary separation. The
proposed method can be applied for routine analysis of
pharmaceutical tablets and for determination of MPZ in
human plasma samples as well.2. Experimental
2.1. Instruments
 TLC scanner 3 densitometer (Camag, Muttenz,
Switzerland).
The following requirements are taken into consideration:
 Slit dimensions: 6  0.45 mm
 Scanning speed: 20 mm s1
 Spraying rate: 10 s mL1
 Data resolution: 100 mm step1
 Band width: 6 mm
 Result output: chromatogram and integrated peak area
 A sample applicator for TLC Linomat IV with 100 mL syringe
(Camag, Muttenz, Switzerland).
 HPTLC aluminium plates (20  20 cm) coated with 0.25 mm
silica gel 60 F254 (Merck, Germany).
UV lamp with short wavelength 254 nm (Vilber Lourmat,
Marne La Vallee, Cedex, France).
 Sonix TV ss-series ultrasonicator (USA).tive degradate (Deg I) and alkaline degradate (Deg II).
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2.2.1. Pure standard
MPZ was kindly supplied by Amriya Pharmaceutical In-
dustries, Alexandria, Egypt. Its purity was found to be 99.00%
according to the company’s analysis certificate.
2.2.2. Pharmaceutical formulation
Vogalib tablets (Batch No. N0348) is labelled to contain 7.5mg
of MPZ manufactured by Cephalon Pharmaceutical Industries
Co., Maisons-Alfort, France.
2.2.3. Chemicals
All chemicals used throughout this work were of analytical
grade and the solvents were of analytical grade.
 Methanol (E.Merck, Germany), sodium hydroxide, hy-
drochloric acid, chloroform, 30% hydrogen peroxide so-
lution and ammonia solution (Specific gravity 0.91, 33%)
(El-Nasr Pharmaceutical Chemicals Co., Abu-Zabaal,
Cairo, Egypt).
 Human plasmawas obtained fromVACSERA (Cairo, Egypt).2.2.4. Preparation of degradation products
2.2.4.1. Preparation of oxidative degradation product (Deg I).
Asmentioned in the literature (Metwally et al., 2006); 0.5 gofpure
MPZ was dissolve in 50 mL 1 M HCl, and 10 mL 30% hydrogen
peroxide solution were added. An orange colour is produced
which fades after about 20 min. Complete oxidation was fol-
lowed up via TLC using chloroformemethanoleammonia solu-
tion (12:2:0.1, by volume) as developing system till complete
disappearance of MPZ spot. The solution was neutralized with
2MNaOH solution till pH¼ 7.5 thenDeg I (oxidative degradation
product) was extracted with multiple fractions of chloroform
(430mL).Theextractwasevaporatedat roomtemperatureand
the pale yellowish white residue was collected and identified
with IR and Mass spectrometry; Figs. 2 and 3.
2.2.4.2. Preparation of alkaline degradation product (Deg II).
0.5 gofpureMPZwas refluxedwith100mLof1MNaOHsolution
for 8 h away from light. NaOH solution was degassed by ultra-
sonication for 30 min to remove any air dissolved oxygen to
avoid formationof any tracesofDeg I.Alkalinedegradationwas
followed up with TLC using chloroformemethanoleammonia
solution (12:2:0.1, by volume) as a developing system till com-
plete fading of dug spot and appearance of a new spot with
evolution of ammonia odour. After complete degradation, the
solution was neutralized with 1 M HCl solution to pH 6 to pre-
cipitate the hydrolytic degradation product, filtered, washed
with distilledwater and dried to obtain Deg II then subjected to
IR and Mass spectrometry; Figs. 2 and 3.
2.3. Standard solutions
2.3.1. Stock standard solution of MPZ, Deg I and Deg II
(1 mg mL1)
0.1 g of each of MPZ, Deg I and Deg II were accurately trans-
ferred into three separate 100-mL volumetric flasks, dissolved
in and diluted to volume with methanol.2.3.2. Stock standard solution of MPZ for plasma
(10 mg mL1)
1 g of MPZ was accurately transferred into 100-mL volumetric
flask, dissolved in and diluted to volume with methanol.
2.3.3. Working standard solution of MPZ, Deg I and Deg II
(100 mg mL1)
10 mL of MPZ, Deg I and Deg II stock solutions were accurately
transferred into three separate 100-mL volumetric flasks and
completed to volume with methanol.2.4. Method preparations
2.4.1. Linearity and construction of calibration curve
Into a set of 10-mL volumetric flasks, different aliquots equiv-
alent to 0.4e1.4mgofMPZwere accurately transferred from its
standard stock solution (1 mg mL1), and volume was
completedwithmethanol. 10mLof eachsolutionwasapplied to
HPTLC plates as bands of 6 mm width using a Camag
Linomat IV applicator. The bandswere spaced 5mmfromeach
other and 15 mm apart from the bottom edge of the plate.
Linear ascending development was performed in a chro-
matographic chamber previously saturated with chlor-
oformemethanoleammonia solution (12:2:0.1, by volume) as a
developing system for 1 h at room temperature to a distance of
8 cm. The integrated peak areas were recorded using scanning
wavelength at 254 nm under the specified instrumental con-
ditions. The calibration curve was constructed by plotting the
integrated peak area/104 versus the corresponding concentra-
tion of MPZ and the regression equation was computed.
2.4.2. Assay of laboratory-prepared mixtures
Different aliquots equivalent to 0.5e1.2 mg of MPZ were accu-
rately transferred from its stock standard solution (1mgmL1)
Into a series of 10-mL volumetric flasks, then aliquots equiva-
lent to 0.2e1.0 and0.2e1.2mgwere added fromDeg I andDeg II
stock solutions (1 mg mL1) respectively. Finally, volume was
completed with methanol to obtain mixtures of different
concentrations of MPZ and its degradation products.
The procedure mentioned under linearity was followed for
the laboratory-prepared mixtures by applying 10 mL of each
mixture solution to HPTLC plates under the specified condi-
tions mentioned before. The integrated peak areas of the
separated bands were recorded and the concentration of MPZ
in each mixture was calculated from its corresponding
regression equation.
2.4.3. Application to human plasma
Into a series of 10-mL volumetric flasks, 1-mL blank (drug-
free) human plasma sample was spiked with different con-
centrations of MPZ from its stock solution (1 mg mL1); the
volume was completed to the mark with methanol to provide
final concentrations from 0.4 to 1.4 mg mL1. The flasks were
shaken vigorously then centrifuged at 3000 rpm for 15 min. 1-
mL of the protein free supernatant was transferred into a se-
ries of 10-mL volumetric flasks, and completed to the volume
with methanol. 10 mL of each solution was applied to HPTLC
plates and the procedure was followed as described under
linearity and the regression equation was calculated.
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different concentrations of MPZ within its linearity range in
plasma.
2.4.4. Application to pharmaceutical formulation
Twenty tablets of Vogalib were powdered and mixed well.
Accurately weighed amount of the powdered tablets equiva-
lent to 100 mg of MPZ was transferred into 100-mL volumetric
flask. 75 mL methanol was added and ultrasonicated for
30 min, cooled and completed to volume with methanol. The
solution was filtered and diluted to obtain 100 mg mL1 work-
ing solution using methanol as a solvent. The plate applica-
tion procedure of the suggested method was followed then
MPZ concentration was calculated using its corresponding
regression equation.
2.5. Method optimization
2.5.1. Mobile phase
Different developing systems of different composition and
ratios were tried e.g. chloroformemethanol (6:4, v/v)
(Metwally et al., 2006), chloroformemethanol (8:2, v/v),
chloroformemethanoleacetic acid (10:2:0.1, by volume),
chloroformeacetoneetriethylamine (10:2:0.1, by volume) and
chloroformemethanoleammonia solution (12:2:0.1, by vol-
ume) to obtain optimum separation between MPZ and its
degradation products.
2.5.2. Scanning wavelength
Different scanning wavelengths were tried, like 265, 254 and
365 nm to obtain good sensitivity ofMPZwithminimumnoise.
2.5.3. Band dimensions
While applying samples as bands, it should be taken into
consideration the slight spread of the developed bands due to
ordinary diffusion so the bandwidth and interspaces between
bands should be chosen carefully to avoid spread of bands
outside the scanning tracks and interference between adja-
cent bands. Different band dimensions were tested in order to
obtain sharp and symmetrical separated peaks.
2.5.4. Slit dimensions of scanning light beam
The slit dimensions of the scanning light beam should ensure
complete coverage of band dimensions on the scanned track
without interference of adjacent bands. Different slit di-
mensions were tried.3. Results
3.1. Elucidation of MPZ degradation products’
structures
Metopimazine was subjected to oxidation using hydrogen
peroxide for 5 h giving one degradation product (Deg I) due to
oxidation of sulphur atom. On the other hand, when subjected
to hydrolysis under alkaline-stress condition by refluxingwith
1 M NaOH solution for 8 h, another degradation product (Deg
II) was produced due to cleavage of terminal amide bond.
Degradation pathway of MPZ is shown in Fig. 1. Thedegradation products were isolated as mentioned before and
characterized by IR- and MS-spectrometry; Figs. 2 and 3.
3.1.1. IR spectral changes
The IRspectrumofMPZshows twocharacteristicbandsatabout
1657.5 and 3429.1 cm1 indicating the presence of the carbonyl
group and the eNH2 of the peripheral amide link respectively.
While the IR spectrum of Deg I shows the same bands of MPZ
indicating thatnochangeshadoccurred to theperipheralamide
link, beside the appearance of a new band at about 1017 cm1
indicating the appearance of a new sulfoxide group due to
oxidation, as shown in Fig. 2(a)e(c). The IR spectrum of Deg II
indicates the disappearance of the sharp 3429.1 cm1 peak
characteristic to eNH2 of MPZ, with the appearance of a broad
3391.8 cm1 peak indicating presence of eCOOH group.
3.1.2. Mass spectrometry
Mass spectra came to affirm the IR interpretations, where the
MS chart of MPZ shows parent peak identified at m/z 445
(corresponding to the molecular weight of MPZ) while MS
chart of Deg I formed under oxidation shows parent peak at
m/z 461 (corresponding to the molecular weight of Deg I) and
that of Deg II shows parent peak at m/z 446 corresponding to
its molecular weight as well. Mass spectra are shown, in
Fig. 3(a)e(c).3.2. Method optimization results
In order to optimize the developed HPTLC method, it was
necessary to investigate the effect of different variables.
Studying the optimum parameters for maximum separation
was carried out where the best developing system was found
to be chloroformemethanoleammonia solution (12:2:0.1, by
volume). This selected mobile phase allowed good separation
betweenMPZ and its degradation productswith good Rf values
without tailing of the separated bands, as shown in Fig. 4. It
was found that presence of ammonia in the developing sys-
tem is essential for separation of Deg II.Where thewavelength
254 nmwas found to be the bestwavelength for scanning of all
components with good sensitivity of MPZ and peaks were
sharp and symmetrical with minimum noise, as shown in
Fig. 5. The optimum band width chosen was 6 mm and the
interspace between bands was 5 mm, where 6 mm  0.45 mm
proved to be the slit dimensions of choice which provided
highest sensitivity.3.3. Analysis results
This proposed method offers high sensitivity and selectivity
for analysis of MPZ in presence of its degradates using chlor-
oformemethanoleammonia (12:2:0.1, by volume) as devel-
oping system followed by densitometric measurement of
bands at 254 nm. The degradation productswerewell resolved
from the pure drug with significantly different Rf values (MPZ,
Rf ¼ 0.58, Deg I, Rf ¼ 0.35 and Deg II, Rf ¼ 0.03).
The calibration curve for MPZ was constructed by plotting
the integrated peak area/104 versus the corresponding con-
centrations of MPZ in the range of 0.4e1.4 mg band1 with
accuracy of mean percentage recovery 100.10  0.941, Fig. 6.
Fig. 4 e 3D HPTLC chromatogram of separated peaks of MPZ (Rf [ 0.58), Deg I (Rf [ 0.35) and Deg II (Rf [ 0.03) using
chloroformemethanoleammonia solution (12:2:0.1, by volume) as a developing system at 254 nm.
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regression equation:
A ¼ 0:8363Cþ 0:3596; r ¼ 0:9998Fig. 5 e 2D HPTLC chromatogram of separated peaks of MPZ (R
chloroformemethanoleammonia solution (12:2:0.1, by volume)where A is integrated peak areas/104, C is the concentration in
mg band1 and r is the correlation coefficient.
The proposed HPTLC method was applied for determina-
tion of MPZ in presence of its degradation products, in
different laboratory-prepared mixtures containing differentf [ 0.58), Deg I (Rf [ 0.35) and Deg II (Rf [ 0.03) using
as a developing system at 254 nm.
Fig. 6 e HPTLC chromatogram of MPZ in the concentration range (0.4e1.4 mg bandL1) using
chloroformemethanoleammonia solution (12:2:0.1, by volume) as a developing system at 254 nm.
b e n i - s u e f u n i v e r s i t y j o u r n a l o f b a s i c a n d a p p l i e d s c i e n c e s 3 ( 2 0 1 4 ) 5 2e6 2 59ratios of them, with mean percentage recovery 100.19  1.383,
Table 1.
To check the validity of the method it was applied for
determination of MPZ in its pharmaceutical formulation
(Vogalib Tablets) with mean percentage recovery
96.60  1.223, Table 2. Furthermore, the standard addition
technique was performed to assess the accuracy with mean
percentage recovery 100.05  1.198, Table 2. The proposed
method was compared to the reported HPTLC method and
result is shown in Table 3.
The proposed HPTLC method was applied for determina-
tion of MPZ in spiked human plasma in the concentration
range of 0.4e1.4 mg band1 with accuracy of mean percentage
recovery 100.49  1.592, Table 4. The concentration of MPZ
was calculated from the following regression equation:
Y ¼ 0:6081C 0:0201; r ¼ 0:9997
where Y is integrated peak areas/104, C is the concentration in
mg band1 and r is the correlation coefficient.Table 1 e Determination of Metopimazine in presence of Deg I a
method.
Ratio MPZ:Deg I:Deg II Concentration (mg band1)
MPZ Deg I Deg
4:1:1 0.8 0.2 0.2
1:1:1 0.6 0.6 0.6
2:1:2 1.2 0.6 1.2
1:2:1 0.5 1.0 0.5
3:1:1 1.2 0.4 0.4
Mean  SD
a Average of 3 determinations.4. Discussion
Thin layer chromatographymade a great progress and attained
awide acceptance as amajor analytical tool for both qualitative
and quantitative methods of analysis and became a well
establishedmethod for theassay of drugs inmixture (Poole and
Poole, 1989). It has many applications in the field of pharma-
ceutical studies which include: stability, impurities, synthetic
drugs, pharmacokinetic, enantiomeric purity and drug moni-
toring in biological fluids (Mincsovics et al., 2001) (Aboul Enein
et al., 2003). Accordingly HPTLC became a method of choice to
use for analysis of our presentedmixtures.
The International Conference on Harmonization (ICH)
guideline “Stability testing of new drug substances and prod-
ucts” requires the stress testing to be carried out to elucidate
the inherent stability characteristics of the active substance
(ICH, 2005), hence; MPZ was subjected to oxidation and alka-
line degradation. Being a phenothiazine derivative; it is liable
to oxidation with hydrogen peroxide at room temperaturend Deg II in laboratory-preparedmixtures by the proposed
MPZ founda (mg band1) Recovery % of MPZ
II
0.808 101.00
0.591 98.50
1.211 100.92
0.508 101.60
1.187 98.92
100.19  1.383
Table 2 e Determination of MPZ in its pharmaceutical formulation by the proposed method and application of standard
addition technique.
Pharmaceutical formulation HPTLC densitometric method
Taken (mg band1) Founda (mg band1) Founda %  SD Added (mg band1) Recoveryb %
Vogalib tablets claimed
to contain 7.5 mg of
MPZ/tablet (Batch No. N0348)
0.60 0.58 96.67  1.223 0.40 100.29
0.50 98.75
0.60 101.11
Mean  SD 100.05  1.198
a Average of 6 determinations.
b Average of 3 determinations.
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being an amide; in alkaline condition the drug undergoes
hydrolysis into its corresponding acid (Deg II) due to cleavage
of amide linkage with evolution of ammonia odour. Mass and
IR spectra of MPZ, Deg I and Deg II confirm the expected
degradation pattern, Figs. 1e3.
Up to our knowledge, no method was reported for the
determination of MPZ in presence of both its oxidative and
alkaline degradation products; (Deg I) and (Deg II) respectively.
Onlyonemethodhasbeenreported fordeterminationofMPZ in
presence of its oxidative degradation product (Deg I) 0 without
application to human plasma, and the reported HPLC method
determinedMPZinpresenceofaciddegradationproduct (Deg II)
(Angelo et al., 1989), where those reported TLC and HPLC
methods didn’t take into account to separate MPZ from both
Deg I andDeg II. Accordingly therewas a need to develop a new
analytical procedure that will serve as a reliable, accurate and
sensitive stability indicating method for the determination of
MPZ in presence of its different degradation products.
This method offered high sensitivity and selectivity for
analysis of MPZ in presence of its degradation products (Deg I
and Deg II) using chloroformemethanoleammonia solution
(12:2:0.1, by volume) as a developing system, where good
separation was obtained by the difference in the retention
factor (Rf) values of MPZ (MR ¼ 8 cm, Rf ¼ 0.58), Deg I
(MR ¼ 8 cm, Rf ¼ 0.35) and Deg II (MR ¼ 8 cm, Rf ¼ 0.03) as
shown in Figs. 4 and 5. In the presented work, samples areTable 3e Statistical comparison of the results obtained by
applying the proposed method and the reported method
for the analysis of MPZ in pharmaceutical formulation.
Item HPTLC densitometric
method
Reported
methodb
Mean 96.60 97.00
SD 1.223 1.287
Variance 1.496 1.656
n 6 6
t-Test
(2.228)a
0.552 e
F-test
(5.050)a
1.106 e
a The values between parenthesis are corresponding to the theo-
retical values of t and F (P ¼ 0.05).
b TLC densitometric determination of MPZ using chlor-
oformemethanol (6:4, v/v) as a developing system and detection at
265 nm (Metwally et al., 2006).applied as bands using TLC Linomat IV sampler with 100 mL
syringe (Camag), where bands have several advantages over
spots as proved in the literature (Sethi, 1996).
The linearity of the proposed method was evaluated by
analyzing different concentration of MPZ. Good linearity is
evident from the high value of the correlation coefficient and
low value of intercept. Descriptive statistics of the regression
show low values of standard error of intercept and slope
which reveal high accuracy with minimum deviations and
low scattering of the calibration points, Table 5.
Results given in Table 1 show that the method can be
successfully applied for determination of MPZ in presence
of its degradation products (Deg I and Deg II). Since the
method could effectively separate the drug from its
degradation products, it can be employed as a stability
indicating one.
Results given in Table 2 show that the suggested method is
valid and applicable for the analysis of MPZ in Its pharma-
ceutical formulation (Vogalib tablets) with an acceptable
percentage recovery. Moreover, the validity of the proposed
method was assessed by applying the standard addition
technique, which showed accurate results and there was no
interference from tablet excipients as shown in Table 2.
The developed HPTLC densitometric method has the
advantage of being highly sensitive for determination of
MPZ which allows the determination of MPZ in spiked
human plasma that can be applied to a pharmacokinetic
study and therapeutic monitoring of the drug, as shown in
Table 4.
Results obtained by the suggested HPTLC densitometric
method for determination of MPZ in its pharmaceutical
formulation were statistically compared with those obtained
by applying the reported TLC method (Metwally et al., 2006).
The calculated t- and F-values (Miller and Miller, 2000) were
found to be less than the theoretical ones, confirming accu-
racy and precision at 95% confidence level, as given in TableTable 4 e Determination of MPZ in human plasma by the
proposed HPTLC densitometric method.
Added (mg band1) Founda Recovery %
0.4 0.408 102.00
0.8 0.786 98.25
1.0 1.010 101.00
1.4 1.410 100.72
Mean  SD 100.49  1.592
a Using the equation: Y ¼ 0.6081C  0.0201.
Table 5 e Assay parameters and method validation for
the determination of pure sample of MPZ by the proposed
method.
Parameters HPTLC densitometric
method
Range (mg band1) 0.4e1.4
Linearity
Slope 0.8363
Intercept 0.3596
Standard error of slope 0.0066
Standard error of intercept 0.0069
Correlation coefficient (r) 0.9998
Accuracy (mean  SD) 100.10  0.941
Selectivity (mean  SD) 100.39  1.201
Precision (%RSD)
Repeatabilitya 0.985
Intermediate precisionb 1.112
Application to plasma
(mean  SD)
100.49  1.592
LOD (mg band1) 0.06
LOQ (mg band1) 0.20
a The intraday (n ¼ 3), average of three different concentrations
repeated three times within day.
b The interday (n ¼ 3), average of three different concentrations
repeated three times in three successive days.
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and accurate as the reported TLC method (Metwally et al.,
2006).Table 6 e Parameters of system suitability of the
developed HPTLC densitometric method for the
determination of MPZ in presence of its degradation
products (Fried and Sherma, 1999).
Parameters MPZ Deg I Deg II
Symmetry factor 1.01 0.98 1.00
Resolution (Rs) 2.56 4.92
Selectivity (a) 1.66 11.67
Capacity factor (K) 0.72 1.85 32.335. Method validation
Method validation was performed according to the interna-
tional conference on harmonization (ICH) guidelines (ICH,
2005) for the proposed method.
Linearity: it was evaluated by analyzing different concen-
trations of MPZ in the range of 0.4e1.4 mg band1. Each con-
centration was repeated 3 times. The assay was performed
according to the experimental conditions previously
described, Table 5.
Precision: repeatability of three concentrations of MPZ (0.4,
0.8 and 1 mg band1) was performed by 3 replicate de-
terminations to estimate intraday variation and 7 replicate
determinations on different 4 days to estimate interday vari-
ation. The coefficient of variation at these concentration levels
was calculated as shown in Table 5.
Accuracy: it was assessed by the standard addition tech-
nique and through analysis of market pharmaceutical
formulation by the proposed method. The resulting mixtures
were assayed and the results obtained were compared to
those expected. The good recoveries with the standard addi-
tion method given in Tables 2 and 5 suggest good accuracy of
the proposed method.
Selectivity: it was evaluated by analysis of different
laboratory-prepared mixtures of MPZ and its degradation
products within the linearity range. Satisfactory results were
obtained as shown in Table 1.Robustness: the robustness of an analytical procedure is a
measure of its capacity to remain unaffected by small, delib-
erate variations in method parameters and provides an indi-
cation of its reliability during normal usage. To determine the
robustness of the method, the experimental conditions were
deliberately changed and the resolution of MPZ and its
degradation products were evaluated. The organic strength of
the developing system was deliberately changed by 0.5 mL
and it has no significant effect on Rf values or symmetry of the
peaks. However, small changes in the volume of ammonia
solution greatly affect separation of Deg II.
Detection and quantitation limits: both were determined
experimentally for theproposedmethod.Thedetection limit is
defined as the concentration of the analyte producing a signal
which is at least three times the baseline noisemeasured from
peak to peak. The quantitation limit is defined as the concen-
tration of the analyte producing the signal which is at least ten
times the baseline noise (USP, 2007), Table 5.
Stability: Degassing of solvents by ultrasonication for
20 min provide protection to MPZ against oxygen dissolved.
MPZ working solutions showed no chromatographic changes
when kept away from light for 2 days at room temperature
(stability indicating method).
System suitability: USP (USP, 2007) states that system suit-
ability tests are an integral part of liquid chromatographic
methods. They are used to verify that the resolution and
reproducibility of the chromatographic system are adequate
for the analysis to be done. Parameters including capacity
factor (K), resolution (Rs), peak symmetry and selectivity factor
(a) were calculated using 1.0 mg band1 of MPZ (Fried and
Sherma, 1999). The resolution is always above two, the
selectivity more than one and an accepted value for capacity
factor and symmetry factorwas obtained forMPZ, as shown in
Table 6.6. Conclusion
The proposed method provides sensitive, selective, accurate,
and reproducible means for determination of MPZ in the
presence of its degradation products using HPTLC densito-
metric technique. HPTLC densitometric method has the
advantage that several samples can be run simultaneously
using a small quantity of developing system and that it can
provide high sensitivity and selectivity. The proposedmethod
has the advantages over the reported TLC method in that it
offers detection of both degradation products (Deg I and Deg
II). Moreover, it offers a means for analysis of MPZ in human
plasma samples which can be applied to pharmacokinetic
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obtained indicate that the introducedmethod can be classified
amongst the highly selective and sensitive procedures. These
merits suggest the use of the proposed method in routine and
quality control analysis without interference of commonly
encountered pharmaceutical formulation additives.r e f e r e n c e s
Aboul Enein HY, El-Awady MI, Heard CM. Enantiomeric resolution
of some 2-arylpropionic acids using L-()-serine-impregnated
silica as stationary phase by thin layer chromatography. J
Pharm Biomed Anal 2003;32:1055e9.
Angelo HR, Herrstedt J, Joergensen M. High-performance liquid
chromatographic method with fluorescence detection for the
simultaneous determination of metopimazine and its acid
metabolite in serum. J Chromatogr Biomed Appl 1989;88:472e7
(J Chromatogr 496).
Budavaried S. The Merck index, an encyclopedia of chemicals,
drugs and biologicals. 14th ed. Whitehouse Station, NJ, USA:
Merck & Co., Inc.; 2006. p. 6149.
Fried B, Sherma J. Thin layer chromatography, vol. 81. New York:
Marcel Dekker; 1999. pp. 11e9.
Gazy AA, Hassan EM, Abdel-Hay MH, Belal TS. Differential pulse
cathodic voltammetric determination of floctafenine and
metopimazine. J Pharm Biomed Anal 2007;43:1535e9.ICH. Q2 (R1) validation of analytical procedures: text and
methodology, ICH harmonized tripartite guideline; 2005.
Martindale KP. The complete drug referenceIn The extra
pharmacopoeia. 34th ed., vol. 3. Royal Pharmaceutical Society;
2005. p. 1276.
Metwally FH, Abdelkawy M, Naguib IA. Development and
validation of three stability indicating analytical methods for
determination of metopimazine in pharmaceutical
preparation. Bull Fac Pharm Cairo Univ 2006;44:1e15.
Miller JC, Miller JN. Statistical and chemometrics methods for
analytical chemistry. 4th ed. London: Pearson Education Ltd.;
2000. p. 98.
Mincsovics E, Dalmadi-Kiss B, Morovjan G, Balogh-Nemes K,
Klebovich IA. New tool in metabolism research:
combination of OPLC on-line radioactivity detection with
HPLC-RD technique. J Planar Chromatogr Mod TLC
2001;14:312e7.
Pharmacopee Francaise. X-eme ed. Paris: L’ADRAPHARM; 1985
(Metopimazinum 1e2).
Poole CF, Poole SK. Progress in densitometry for quantitation in
planar chromatography. J Chromatogr Biomed Appl
1989;492:539e84.
Sethi PD. HPTLC high performance thin layer chromatography.
New Delhi, India: CBS Publishers and Distributors; 1996.
pp. 19e22.
The United States Pharmacopeia and National Formulary. Asian
edition. USP 30-NF 25. The official compendia of standards,
vol. 1. Rockville, MD: The United States Pharmacopeial
Convention Inc.; 2007. pp. 252e3.
